Abstract
From the private practices of Lansing community pediatricians two groups of 33 pediatric ambulatory patients with Group A β-hemolytic streptococcal pharyngitis matched with respect to age, sex, race, socioeconomic status, duration of symptoms prior to treatment, and WBC at onset of treatment were randomized into 10 B.I.D. or Q.I.D. Cephalexin treatment regimens (B.I.D. = 10-15 mg/kg/dose, Q.I.D. = 5-8 mg/kg/dose). Compliance was assured by followup phone calls and inspection of medication containers at followup visits. Excellent clinical responses and bacteriologic cure (negative culture at day 14 and 28) occurred in 31/33 B.I.D. patients and 33/33 Q.I.D. patients. One clinical and bacteriologic failure, and one bacteriologic “relapse” (positive culture on day 28) occurred in the B.I.D. treatment group. No significant toxicity occurred in any of the study patients. These findings suggest that (1) a B.I.D. Cephalexin regimen is comparable to a Q.I.D. regimen in the treatment of Group A β-hemolytic streptococcal pharyngitis, (2) further evaluations of B.I.D. Cefalexin regimens in ambulatory patients are warranted, and (3) controlled clinical trials can be practical, productive and cost-effective utilizing the private physicians' practices as a source of patient populations.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Anderson, D., Hollister, S., Comstock, H. et al. 751 TREATMENT OF STREPTOCOCCAL PHARYNGITIS WITH B.I.D. CEPHALEXIN. Pediatr Res 12 (Suppl 4), 489 (1978). https://doi.org/10.1203/00006450-197804001-00756
Issue date:
DOI: https://doi.org/10.1203/00006450-197804001-00756
